P/E ratio for Illumina (ILMN)
P/E ratio as of December 2022 (TTM): -8.00
According to Illumina's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.00265. At the end of 2021 the company had a P/E ratio of 74.7.
P/E ratio history for Illumina from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 74.7 | -9.5% |
| 2020 | 82.6 | 69.54% |
| 2019 | 48.7 | -8.72% |
| 2018 | 53.4 | 22.13% |
| 2017 | 43.7 | 7.85% |
| 2016 | 40.5 | -32.66% |
| 2015 | 60.2 | -16.22% |
| 2014 | 71.8 | -35.06% |
| 2013 | 111 | 142.71% |
| 2012 | 45.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Thermo Fisher Scientific TMO | 31.4 | -492.37% | 🇺🇸 USA |
 Agilent Technologies A | 34.5 | -530.63% | 🇺🇸 USA |
 Quest Diagnostics
DGX | 14.2 | -277.73% | 🇺🇸 USA |
 Danaher DHR | 29.8 | -472.47% | 🇺🇸 USA |
 PerkinElmer
PKI | 27.6 | -445.21% | 🇺🇸 USA |
 Translate Bio
TBIO | N/A | -100.00% | 🇺🇸 USA |
 Pacific Biosciences
PACB | -7.58 | -5.26% | 🇺🇸 USA |
 Luminex LMNX | N/A | -100.00% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.